Clinical Trials in France / NCT05859191
Recruiting
Observational
Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus
NCT05859191 · tracked via the Priya Life Science France tracker
Condition(s) studied
Systemic Lupus ErythematosusPhysiopathology
Investigational drug(s) / intervention(s)
Blood sample: Three extra tubes of blood will be taken at each consultation or inpatient visit when routine blood samples are taken as part of lupus monitoring.
Study summary
This study evaluates the variation of expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells Expressing an Invariant T Receptor (iNKT) and monocytes along with the surface expression of Fc gamma type II receptor (RII) and RIII in active or newly diagnosed lupus patients compared to inactive lupus patients.
Eligibility
Inclusion Criteria:
* Age ≥ 18 years
* Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's
* Lupus patient, newly diagnosed or known, untreated or in relapse
* Lupus patient considered stable by the treating practitioner
* Requiring blood sampling for follow-up
Exclusion Criteria:
* Main autoimmune disease other than lupus
* Patient under legal protection, guardianship or curators
* Opposition to data processing
Primary outcome measure(s)
- FcRn Expression analysis in Circulating iNKT lymphocytes — through study completion, an average of 3 year
by flow cytometry (mean fluorescence intensity) - FcRn Expression analysis in circulating monocytes — through study completion, an average of 3 year
by flow cytometry (mean fluorescence intensity) - FcgammaRII Expression analysis in Circulating iNKT lymphocytes — through study completion, an average of 3 year
by flow cytometry (mean fluorescence intensity) - FcgammaRII Expression analysis in circulating monocytes — through study completion, an average of 3 year
by flow cytometry (mean fluorescence intensity) - FcgammaRIII Expression analysis in Circulating iNKT lymphocytes — through study completion, an average of 3 year
by flow cytometry (mean fluorescence intensity) - FcgammaRIII Expression analysis in in circulating monocytes — through study completion, an average of 3 year
by flow cytometry (mean fluorescence intensity)
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| University Hospital | Tours | France | Recruiting |
More University Hospital, Tours trials in France
Other trials for the same condition
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)
Active, not recruiting
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05859191 on ClinicalTrials.gov ↗ ← All trials in France